Child vaccinations down in DR Congo, and COVID-19 is not helping: UNICEF
Fewer children are getting vaccinated in the Democratic Republic of the Congo (DRC) and the COVID-19 pandemic is almost certainly going to make matters worse, the United Nations Children’s Fund (UNICEF) says. If the trend continues, it could trigger a resurgence in deadly childhood diseases such as polio, chickenpox, measles, yellow fever, hepatitis B, diphtheria, tetanus, whooping cough and meningitis. (Source: UN News Centre - Health, Poverty, Food Security)
Source: UN News Centre - Health, Poverty, Food Security - May 15, 2020 Category: International Medicine & Public Health Source Type: news
USPSTF: Screen for HBV Infection in People at Increased Risk
The U.S. Preventive Services Task Force recently issued a draft recommendation statement and draft evidence review on screening for hepatitis B virus infection in nonpregnant adolescents and adults. (Source: AAFP News)
Source: AAFP News - May 12, 2020 Category: Primary Care Source Type: news
USPSTF Recommends Hep B Screening for Those at Increased Risk
TUESDAY, May 5, 2020 -- The U.S. Preventive Services Task Force (USPSTF) recommends screening adolescents and adults at increased risk for hepatitis B virus (HBV) infection. These findings form the basis of a draft recommendation statement published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 5, 2020 Category: Pharmaceuticals Source Type: news
What Are the Complications of Inhalant Abuse?
Discussion
Hydrocarbons (HC) are organic compounds that are abused because they produce a euphoric effect, usually quickly, are low cost and easily obtained. They are commonly abused by adolescents and use in the US is either stable or increasing.
Volatile HC rapidly distribute throughout the body which produces euphoria in seconds to minutes. There are 3 ways that HC are inhaled:
Sniffing – directly inhaling the HC from the container. This has the lowest HC concentration.
Huffing – a cloth is saturated with the HC and then the cloth is held to the nose and mouth and inhaled. This has a higher concentration ...
Source: PediatricEducation.org - May 4, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Twinrix (Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 27, 2020 Category: Drugs & Pharmacology Source Type: news
Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion available...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer
Basel, 21 April 2020 - Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced US Food and Drug Administration (FDA) approval for the cobas ® HPV test for use on the fully automated, high-throughput cobas® 6800/8800 Systems. The cobas® HPV test identifies women at risk for cervical cancer by detecting the presence of high-risk human papillomavirus (HPV) DNA in cervical samples. Persistent high-risk HPV infections can develop into pre cancerous lesions and, if left untreated, these lesions can progress to cervical cancer.“The approval of our HPV test for the cobas 6800 and 8800 Systems enables molec...
Source: Roche Media News - April 21, 2020 Category: Pharmaceuticals Source Type: news
Scientists explore using 'own' immune cells to target infectious diseases including COVID-19
(Duke-NUS Medical School) The engineering of specific virus-targeting receptors onto a patient's own immune cells is now being explored by scientists from Duke-NUS Medical School, as a potential therapy for controlling infectious diseases, including the COVID-19-causing virus, SARS-CoV-2. This therapy that has revolutionised the treatment of patients with cancer has also been used in the treatment of other infectious diseases such as Hepatitis B virus, as discussed by the School's researchers in a recent commentary. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 21, 2020 Category: Infectious Diseases Source Type: news
Collaboration Offers FPs Guidance on Hepatitis B Management
A multidisciplinary panel of hepatitis B virus experts has collaborated to produce a new guidance document on HBV prevention, diagnosis and management for family physicians and other primary care clinicians. (Source: AAFP News)
Source: AAFP News - April 8, 2020 Category: Primary Care Source Type: news
FDA accepts Roche ’s New Drug Application for Xofluza (baloxavir marboxil) for the treatment of influenza in children
Basel, 27 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) as well as two supplemental New Drug Applications (sNDA) for Xofluza® (baloxavir marboxil). The FDA accepted a NDA for a new formulation of Xofluza as one-dose granules for oral suspension (2 mg/mL), potentially offering a more convenient option for children and those who have difficulty swallowing. In addition, the application seeks approval of Xofluza for the treatment of acute uncomplicated influenza in otherwise healthy children aged one to l ess than 12 y...
Source: Roche Investor Update - March 27, 2020 Category: Pharmaceuticals Source Type: news
CDC: Prevalence of Any Past, Present Hep B Infection 4.3 Percent
WEDNESDAY, March 25, 2020 -- The prevalence of any past or present hepatitis B virus (HBV) infection was 4.3 percent among U.S. adults during 2015 to 2018, according to a March data brief published by the U.S. Centers for Disease Control and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 25, 2020 Category: Pharmaceuticals Source Type: news
Janssen Announces Health Canada Approval of CABENUVA ™, the First Long-Acting Regimen for the Treatment of HIV
Cork, Ireland, March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Health Canada has approved CABENUVA™ (cabotegravir and rilpivirine extended release injectable suspensions), the first and only once-monthly, long-acting regimen for the treatment of HIV-1 infection in adults. CABENUVA™ is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]). CABENUVA™, a co-packaged kit with two separate inj...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Hepatitis B prophylaxis in adolescents who present for examination after alleged sexual assault - Jones ME, Tully JM.
AIM: In Australia, the risk of hepatitis B virus (HBV) transmission from single sexual contact is low. This, combined with assumed widespread immunity from vaccination, has resulted in a lack of clarity surrounding the necessity for hepatitis B post-exposu... (Source: SafetyLit)
Source: SafetyLit - March 17, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Risk for Liver Cancer Down With Low-Dose Aspirin in Hepatitis B, C
WEDNESDAY, March 11, 2020 -- Low-dose aspirin is associated with a reduced risk for hepatocellular carcinoma among patients with chronic viral hepatitis, according to a study published in the March 12 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2020 Category: Pharmaceuticals Source Type: news
For People With Hepatitis, Daily Aspirin Might Lower Liver Cancer Risk
WEDNESDAY, March 11, 2020 -- People with hepatitis B or C are at greater risk for liver cancer, but a low-dose aspirin a day might significantly lower that risk, a new study suggests.
Over a median of nearly eight years of follow-up, 4% of those... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 11, 2020 Category: General Medicine Source Type: news
